NUVL
Nuvalent, Inc. Class A Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Nuvalent (NUVL) Stock: Buy, Sell, or Hold?
$123.96
+0.02 (+0.02%)
â˛
5d:
+0.15%
30d:
+0.41%
90d:
+19.55%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (64%)
Quality Score
44/100
Position
FAIR
Forward P/E & Valuation
-30.0x
Next 12M consensus est.
Wall Street Target
$125.13
+0.9% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$123.43 / $123.99
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: NUVL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When NUVL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NUVL is currently trading at $123.96, which is considered fair based on recent price action.
Technical Outlook: Technically, NUVL is in a strong uptrend. The price is currently testing key support at $123.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUVL is in a strong uptrend. The price is currently testing key support at $123.43. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
44/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
Trading Range & Key Levels
Support Level
$123.43
Resistance Level
$123.99
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- NEUTRAL: Near Wall St target ($125.12)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-30.00
Wall Street Target
$125.13
(+0.9%)
Share NUVL Analysis
Share this live NUVL analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NUVL)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jun 17, 2026
Daily AI digest
AI Retail Discussion Summary:
A bullish StockTwits message suggests that $CRMD could be the next company to undergo a buyout or deal based on its recent performance. No newsworthy events were found on Yahoo Finance.
Key Retail Themes:
buyout or deal speculation
positive sentiment towards $CRMD
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:50 AM ET
Data refreshes hourly during market hours. Next update: 9:50 AM
Data refreshes hourly during market hours. Next update: 9:50 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUVL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 47 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 63 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 43 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NUVL Research Pages
